Paediatric care

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

Long-acting ART for children is a deferred priority despite achievable dosing

9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris

Chewable raltegravir tablets can be crushed and dispersed in liquid for young children

FDA approves sofosbuvir/ledipasvir and sofosbuvir for children aged 12 to 17

Community presentations: dental care, HIV awareness and access to formula milk

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure is modestly higher in children than adults

New HIV diagnoses in children in UK and Ireland continue to decline

World Health Organisation paediatric dosing tool

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

FDA approves maraviroc for children aged two and older

Raltegravir-based third-line ART in children and adolescents

Raltegravir in HIV-exposed neonates

Virological response without routine viral load monitoring in children: results from the ARROW trial

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

Shortened nine-month MDR-TB treatment works well in children and adolescents

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

The paediatric antiretroviral pipeline

The paediatric tuberculosis treatment pipeline: beyond pharmacokinetics and safety data

No effect of tenofovir on infant bone mineral content in African study

Use of modelling to predicting paediatric dosing of long acting antiretrovirals

Nevirapine dosing for treatment of neonates

Dolutegravir: 48 week results in children age 6 to 12 years old

Substituting lopinavir/ritonavir with efavirenz in children on stable ART

The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression

Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB

Protection against flu but not HBV in vaccinated perinatally HIV-infected children

Raltegravir for neonates will require a complicated dosing regimen

Paediatric dosing of DRV/r

FDA approve additional weight band dosing for children using atazanavir powder

Dispersible tablet formulation of dolutegravir is bioequivalent to the granule formulation

The Pediatric Antiretroviral Pipeline

Momentum in the Pediatric Tuberculosis Treatment Pipeline

Other short reports from BHIVA:

Elvitegravir in children and adolescents

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir superior to nevirapine in children <3 years old: IMPAACT P1060 five year results

Long-term safety and efficacy of tenofovir in children

Drug resistance in children after PMTCT and early treatment

Pharmacokinetics and safety of moxifloxacin in children

TB in the ARROW trial of children on ART

Problems giving current second line TB drugs to children

Infants start ART too late but improvement over time in Southern Africa

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

Rationalising the paediatric antiretroviral formulary in Malawi

Time to first-line failure in the IeDEA cohort

Influence of early ART on antibody detection in children

Wrestling with the implications of the Mississippi case

The paediatric antiretroviral pipeline

Playing catch-up: paediatric tuberculosis treatment pipeline

Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents

Early antiretroviral treatment in infants

Catching up with pathogenesis and cure research from CROI 2014

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

FDA approves raltegravir for children older than 4 weeks

Post navigation